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main categories of risks were identified which could affect on accessibility and
quality named financial, supply, production, storage and logistic risks andin each
category there were several uncertainties. Inflation rate, exchange rate, incorrect
pricing, selection of suppliers, delay in shipment, policy issues, malfunction of
machineries, untrained personnel and inappropriate condition of storage and dis-
tribution are some of risks in different categories. All of these risks had direct or
indirect effect on quality or accessibility of medicines. CONCLUSIONS: Our study
offers risk assessment methodology as a scientific way for identification of uncer-
tainties which affect on quality and accessibility of medicines as two main objec-
tives of national drug policy and also it demonstrated some proper strategies to
mitigate them.
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OBJECTIVES: We examine how much of the cross-country drug price differences
can be explained by macroeconomic conditions (real GDP per capita, openness,
population, and corruption). METHODS: We use the Pricentric® dataset of drug
prices and analyze prices of 13 drug packs across 32 countries at various pack levels
in 2009. The sample is selected by requiring each pack having observations for
more than 20 countries and each country having observations for more than 20
packs. We gather data on real GDP per capita, openness, and population from the
PennWorld Table, and the Corruption Perceptions Index by Transparency Interna-
tional. The analysis has two parts. First, for each drug pack, we regress the log
prices (ex-factory, public, etc) on the four macroeconomic variables. Second, to
achieve better identification, we pool together all data and regress log prices on the
macroeconomic variables and drug fixed effects. RESULTS: For 6 of the 13 packs we
find that the four macroeconomic variables can explain the cross-country price
variations well (with R-squared over 8%). For the other 7 drugs the fit is worse, but
the signs of the coefficients among the 13 packs are in general consistent. The
pooled regression shows the same conclusion that the macroeconomic variables
have strong explanatory power. For thewhole sample, a 1% increase in real GDPper
capita correlates with a 0.15% increase in drug price. Openness has little impact,
while population has a small but significant positive association. A 1% increase in
the corruption index correlates with a 0.3% increase for all prices. CONCLUSIONS:
Controlling for drug fixed effects, macroeconomic variables show statistically sig-
nificant and economically large effects on drug pack prices. In particular, real GDP
per capita and corruption perceptions have large positive impacts suggesting drugs
cost more in either more developed countries or in more corrupted countries.
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THE HIGH COST OF TREATING CANCER: DO MANUFACTURER PRICING POLICIES
TAKE AFFORDABILITY INTO ACCOUNT?
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OBJECTIVES: In 2008, GLOBOCAN estimated 2.8 million new cases of cancer in
China, making up 22% of all global cases. Although the Chinese government has
initiated a number of reforms to improve patient care, oncology drug access re-
mains a significant issue with medicines not being on national lists of essential or
reimbursed drugs. In China, manufacturers often set the price of oncology drugs
free of government mandates as these are not reimbursed. In contrast, in markets
where governments fund cancer treatment (South Korea, Japan, Taiwan), all med-
icines are assessed and undergo price setting/negotiation. Given these dynamics
and discussion by pharma companies to price medicines more in line with afford-
ability, this research explores the price differences for oncology agents across dif-
ferent types of markets taking into account the purchasing power parity and level
of patient access. METHODS: Review current prices of selected oncology agents
and the level of patient access across the Asian markets. Compare uptake of drugs
and identify drivers for access and uptake. Analyze prices relative to purchasing
power parity and compare to US& EU. RESULTS:The price differential across Asian
markets is correlated with lack of reimbursement, i.e., higher prices in countries
where there is no likelihood of reimbursement. In contrast, in countries where
these drugs are reimbursed, prices are tightly controlled and subject to regular
price cuts. Affordability remains the major challenge for access to cancer drugs.
CONCLUSIONS: Currently, innovative cancer drugs are outside the reach of most
Chinese as drug prices are some of the highest in the world. As the government
aims to reimbursemore oncology therapies, it will need to agree withmanufactur-
ers on price levels. Asianmarkets with ability to secure patient access tomedicines
at regulated prices can be useful models for China as the government looks to
improve the system.
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OBJECTIVES:Ourmajor objective of the studywas to assess the budgetary outcome
of implementing the first Hospital Essential Medicines List (HEML) 2011 with a
revised purchase policy in a rural resource limited, district charity hospital in India.
HEML was also compared with national and World Health Organization (WHO)
EMLs. METHODS: Expenditure on medicines purchase for the year of 2010 was
compared for the year 2011 (after the first HEML and revised purchase policy).
Evaluations were done to compare the number of medicines, dosage forms and
fixed drug combinations of tablets and injections. Microsoft Excel 2007 was used to
process the results. RESULTS: There was approximately 40 % reduction in the
money spent on medicines in 2011 when compared to 2010, which was approxi-
mately nine crores of Indian Rupees (approximately 1.7 Million US Dollars). The
number of medicines in 2010 was 1627, which was reduced to 424 in HEML 2011.
WHOEML 2011 has 350 and National Essential Drugs List (NEDL) 2011 of India has
348 medicines. While preparing the HEML, 31 tablets and 14 injections of two-drug
fixed combinationswere removed. The great reductionswere; 51 ointments to 9, 69
drops to 5, 11 paste to 0, 21 solutions to 3 and 14 creams to 1. The dosage forms
removed include elixir, insulin pen, gums, paste, paint, gargle, mouthwash.
CONCLUSIONS: New purchasing policy and implementation of HEML were the
crucial factors in the cost minimization, in our charitable hospital. The WHOEML
2011, NEML 2011 and the HEML 2011 were comparable with few exceptions. Health
care policy makers should note that, use of WHOEML and NEML with local experi-
ence makes implementation of HEML more practical in the countries with limited
professional resources.
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Compliance is an important factor for successful clinical management of schizo-
phrenia. Risperidone long-acting injection (RLAI) can improve compliance com-
pared to oral atypical anti-psychotics and several studies found the use of RLAIwas
associated with reduced hospitalization. RLAI was introduced to Japanese practice
from June 2009 and is currently only available atypical anti-psychotic depot
medication. OBJECTIVES: To assess the impact of RLAI use on hospitalization as a
proxy of relapse in daily practice among Japanese patients with schizophrenia.
METHODS: Mirror image comparison of psychiatric related hospitalization was
made for 6 months before (pre-RLAI) and 6 months after (post-RLAI) the initiation
of RLAI. The data source was commercially available health insurance claims da-
tabase (Japan Medical Data Center, Tokyo; January, 2009 to June, 2011). The inclu-
sion criteria were patients (20-59 years of age) who were diagnosed with schizo-
phrenia (ICD F20 to F29) and who had continuous enrollment of the Group health
insurance for 6 months before and 6 months after the initiation of RLAI. Patients
with long-term hospitalization (6 months) were excluded. Additionally, study
patients were restricted to have at least 3 month continuous treatment with RLAI.
In the analysis the initiation of RLAI during hospitalization contributed to pre-RLAI
hospitalization because previous treatment was considered as failure. RESULTS: A
total of 25 patients from 58 patients who were initiated on RLAI met the inclusion
criteria. Twenty patients started at outpatient visits and 21 patients continued the
RLAI treatment after 6 months. Mean dose was 33.5mg. The proportion of patients
requiring psychiatric hospitalization was changed from 28% to 8% between pre-
and post-initiating RLAI (P001). The total number of psychiatric hospitalization
was reduced by 82% (11 vs. 2, P0.02). CONCLUSIONS: Switching from oral anti-
psychotics to RLAImay impact on the reduction in hospitalization among Japanese
schizophrenic patients. Further investigation is necessary.
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OBJECTIVES: To estimate the annual prevalence, the related medical costs, and
health care resource utilization of patients diagnosed as herpes zoster (HZ) and
post-herpetic neuralgia (PHN), respectively, with different immune status in South
Korea.METHODS: This study is a retrospective analysis using the Korean National
Patients Sample 2009 database of the Health Insurance Review and Assessment
Service (HIRAK-NPS). Results of the sample databasewere extrapolated to the total
Korean population aged  40 years. HZ and PHN patients were identified from
diagnostic codes, and categorized into three subgroups based on the severity of
immune status; non-compromised, mild to moderate and severe status. Medical
costs included all HZ- or PHN-related costs incurred at medical facilities and med-
ication costs. RESULTS: The prevalence of HZ (or PHN) was 15.53 (or 2.13) per 1000
persons among those aged 40 years in South Korea. The annualmedical costs per
patient for HZ (or PHN)managementwere US$191 (or $177). The average number of
outpatient visits, emergency department visits and hospital admissions of HZ (or
PHN) patients were 3.75, 0.01, and 0.05 (4.44, 0.01, and 0.03) per annum, respec-
tively. With regard to the severity of immunodeficiency, patients with severe con-
ditions were related to higher prevalence rate, medical costs and health care
utilization. CONCLUSIONS: HZ and PHN cause considerable disease burden in
South Korea, especially among immunocompromised population. Considering
rapidly aging population and increasing prevalence of immunosuppressive condi-
tions, the disease burden is likely to increase. The findings of the present study can
serve as important baseline data for policy decision making to reduce the burden,
such as the development of a HZ vaccination recommendation.
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OBJECTIVES: China’s health care expenditure is one of the largest in the world and
is set to grow strongly in the foreseeable future. A greater understanding of the
impact of economic and policy factors on China’s health care expenditure and its
growth trend will help major pharmaceutical firms make strategic plans in the
emerging markets.METHODS: Dynamic least squares regression was used on an-
nual time series data (1970 to 2011). The dependent variable was real per capita
health care expenditure (RPCHE). The explanatory variables included real per cap-
ita GDP (RPCGDP), relative price for consumer health spending (RPCMED) and
lagged variables. The analysis used data fromWHO, China Statistical Yearbook and
IHS Healthcare Forecasting. The main independent variables were RPCGDP and
RPCMED. RESULTS: A negative correlation was found between estimated RPCHE
and RPCMED; and a positive correlation between estimated RPCHE and RPCGDP.
The main results can be summarized as follows: 1) For every 1% rise in the growth
rate of RPCMED, there is a 1.16% decrease in the level of RPCHE, and 2) the income
elasticity of real health care expenditure is 15%. Based on the estimations, forecasts
on total health care expenditureweremade for the forecast period (2012-2020). The
main independent variables—RPCMEDandRPCGDP—were derived from IHSMacro
for the forecast period. To capture health care policy’s impact on health care ex-
penditure, add factors were used in the forecast. According to the forecast, China’s
total health care expenditure is projected to grow 15.8% this year and 14.8% next.
CONCLUSIONS: In terms of economic impact, relative price for consumer health
spending and income play a major role in determining health care expenditure. In
terms of policy impact, China’s health care reform—via massive health insurance
expansion—will be a key driver of health care expenditure growth throughout the
forecast horizon, although there are increasing pressures on pricing and significant
regional disparities.
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HEALTH FINANCING FOR PRISONERS WITH HIV: LESSON LEARNED FROM
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OBJECTIVES:To obtain information on spending onprevention and care-treatment
programs among prisoners in two prisons: Jakarta and Bali and who finance the
program. METHODS: Retrospective data was collected from two prisons: Bali and
Jakarta. Cost was estimated from government and partners perspective. Both
quantitative and qualitative analysis were done. A modified activity-based costing
was done supported with document review and interviews. RESULTS: HIV inter-
vention in Indonesia has been improving with support from the Government and
international partners. At the moment several prisons in Java are chosen as model
for HIV-AIDS programs for prisoners, including VCT, Lab-test, ART, OI treatment
and hospital care. Total spending in Bali was USD 26.239 per-year and unit cost was
USD 78, while in Jakarta unit cost was USD 426. These spending even higher if other
activities such as substitution and treatment at hospital were included. Some pro-
grams such as Methadone theraphy, condom and ART were conducted in collabo-
ration with District Health Office and local hospital, and funded by government.
Interestingly, program for prisoners in Bali includes spiritual theraphy such as yoga
and dancing, initiated using funds from international partners. High cost for CD4
and ART were covered by central government, while operational cost was sup-
ported by local government. Networking with other institution become critical,
since no direct costs actually covered by the prisons themselves. CONCLUSIONS:
Most of program intervention for prisoners supported by external partners. Sus-
tainability issue remain unclear since donor fundingwill be finished soon andmust
be replaced by government. Local government is expected to support continuity of
the program, but regions with low fiscal capacity are not able to ensure program
continuity.
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DOWN-SCHEDULING MEDICINES FROM PRESCRIPTION TO
OVER-THE-COUNTER: WIN-WIN?
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OBJECTIVES: Each year over a million patients in Australia delay seeing a General
Practioner (GP), and a similar number do not fill their prescriptions, because of the
cost. This failure to access necessary medications has economic and morbidity
implications in the long-term. In addition, reduced uptake affects company reve-
nue. Currently theUS Food andDrugAdministration (FDA) is considering a range of
measures to improve access to medicines, including making more drugs used for
common, under-treated conditions, available over-the-counter (OTC). This study
aimed to compare the costs to the patient and potential manufacturer price for a
sample of medicines that are available both OTC and on prescription in Australia.
METHODS: Costs of accessing diclofenac (25mg tablets) and omeprazole (20mg
tablets) via a GP prescription were compared to those for OTC. For medicines ob-
tained on prescription, patient co-payments were sourced from the Pharmaceuti-
cal Benefits Schedule (PBS) website, and the average cost of a GP visit. Costs of OTC
formulations were estimated based on a sample of pharmacies. The resultant cost
to patient and potential price to the manufacturer were calculated and compared.
RESULTS: For patients in Australia, OTC acquisition of medicines was up to 50%
less expensive per tablet than accessing treatment via GP prescription. The per-
tablet savings for patient were greater for omeprazole than for diclofenac. At the
point of sale, the cost per tablet of OTC products was 150%-500% of the ex-manu-
facturer cost for the PBS listed product. Therefore, an OTC strategy also appears to
be a commercially viable for manufacturers, even allowing for a pharmacy
mark-up. CONCLUSIONS: Down-scheduling from prescription-only to OTC may
decrease the direct costs of treatment for patients, while simultaneously increas-
ing the price per tablet to manufacturers: a win-win situation.
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OBJECTIVES: Replacement of Peripheral Venous Catheter (PVC) is sometimes re-
quired prematurely due to extravasation, catheter damage, complications such as
phlebitis. We evaluated the clinical and economic benefits of an integrated closed
intravenous catheter system (CICS) with pre-attached stabilization platform and
extension tube (Catheter A) which may reduce the occurrence of unscheduled
catheter replacement. METHODS: A prospective, open, quasi-random, and con-
trolled study was conducted to compare Catheter A and a conventional PVC (Cath-
eter B) in a 286-bed general hospital in Japan. Patients requiring PVCs for 72 hours
or more were enrolled and assigned to either Catheter A Group (Group A) or Cath-
eter B Group (Group B). Both catheters were secured with the same procedure and
regularly observed until removal. The Kaplan-Meier estimate for the replacement
rates for both catheters for 72 hours was calculated, and the cost difference be-
tween the groups was obtained using product prices and average nursing fees
published by the government. RESULTS: There were 358 patients evaluated: 193 in
Group A and 165 in Group B. One hundred forty three patients in Group A and 109
patients in Group B required catheter replacement because of extravasation, cath-
eter damage, complications, or scheduled catheter removal. The remaining 106
patients from both groups had catheters removed for unexpected reasons such as
earlier end of therapy and self-withdrawal. Excluding those 106 patients, therewas
a significant difference in the catheter survival curves between Group A and B
(p0.01, log-rank test). The total cost of catheter replacement for 72-hour use was
393 yen for Group A and 704 yen for Group B. CONCLUSIONS: The cost difference
between two catheters can be offset by savings generated from a lower event rate.
Along with total cost benefits, the use of CICS is considered to provide improved
safety to patients through decreased complications.
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OBJECTIVES: Febrile neutropenia (FN) is a major complication in cancer patients
treated with chemotherapy, leading to infection-associatedmorbidity andmortal-
ity. Therefore, prophylactic use of granulocyte colony-stimulating factor (G-CSF) is
recommended by recent clinical guidelines tomanage those patientswith high risk
of FN. Uncertainty in selecting patients who need G-CSF prophylaxis, however,
remains in clinical settings. The objectives of this study were to document the
utilization pattern of G-CSF and to analyze the potential risk factors of FN in non-
Hodgkin’s lymphoma (NHL) patients.METHODS: Eligible patients were those who
were older than 18 years, diagnosed with NHL, and initiated a new chemotherapy
regimen in 2010 at amedical center in Taiwan. All chemotherapy cycles received by
our study subjects were divided into two groups based on the occurrence of FN
during each cycle. All patients were followed until all the planned chemotherapy
courses were completed or one year after the first date of chemotherapy regimen.
Differences in patient characteristics between the FN and non-FN group were as-
sessed with chi-square tests for categorical variables and t-tests for continuous
variables. RESULTS: Two hundred and eighty-six courses for G-CSF prophylaxis
were evaluated in 72 patients receiving a total of 432 cycles of chemotherapy reg-
imen. Of these, 38 % of G-CSF was prescribed as primary prophylaxis, and 62 % as
secondary prophylaxis, with an average duration of 3 days. Differences between FN
and non-FN group which is statistically significance were history of chronic renal
failure or anemia (p0.0038, p0.0001), prophylactic use of G-CSF (p0.0192), per-
formance status (p0.0001), numbers of previous neutropenia (p0.0008), baseline
albumin or hemoglobin level (p0.0085, p0.0001). CONCLUSIONS: At this cancer
center in Taiwan, the duration of G-CSF administration is shorter than the recom-
mended. Differences between the two groups may be the possible risk factors, and
need to be further analyzed.
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OBJECTIVES: To compare pharmaceutical company and medical representatives
as drug information source with other conventional and advanced sources being
used by Doctors. METHODS: A total 103 doctors were interviewed personally by
using a structured validated questionnaire developed. Ransom and purposeful
samplingwas used to select the required sample. The data collectedwas evaluated
and represented in the form of total numbers and percentages. RESULTS: Among
103 doctors (52.42% or 54) mentioned that pharmaceutical companies andmedical
representatives are less useful source of information. 58.25% doctors responded
that Pharmaceutical company sponsored Education program as useful. A total of
17.47%mentioned it as very useful source of information for new drugs and 24.27%
doctors mentioned it as less useful. A total of 59.12% doctors mentioned medical
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